110 CHAPTER 4 62 Massari, F. et al. Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. Expert Rev Anticanc 15, 1367-1369, doi:10.1586/14737140.2015.1110488 (2015). 63 Czarnecka, A. M., Niedzwiedzka, M., Porta, C. & Szczylik, C. Hormone signaling pathways as treatment targets in renal cell cancer. Int J Oncol 48, 2221-2235, doi:10.3892/ijo.2016.3460 (2016). 64 Wang, L. X. et al. Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Patho 8, 13374-13380 (2015). 65 Ruan, H. L., Li, S., Bao, L. & Zhang, X. P. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma. Oncogene 39, 6113-6128, doi:10.1038/s41388-020-01409-6 (2020). 66 Mc Namee, N. & O’Driscoll, L. Extracellular vesicles and anti-cancer drug resistance. Bba-Rev Cancer 1870, 123-136, doi:10.1016/j.bbcan.2018.07.003 (2018). 67 Soekmadji, C. & Nelson, C. C. The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer. Biomed Research International 2015, doi:Artn 454837 10.1155/2015/454837 (2015). 68 Beuselinck, B. et al. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int 114, 81-89, doi:10.1111/bju.12494 (2014). 69 Fujita, T. et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 19, 908-913, doi:10.1111/j.1442-2042.2012.03071.x (2012). 70 Wee, P. & Wang, Z. X. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 9, doi:ARTN 52 10.3390/cancers9050052 (2017). 71 Casar, B., Pinto, A. & Crespo, P. Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell 31, 708-721, doi:10.1016/j.molcel.2008.07.024 (2008). 72 Schulze, W. X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1, doi:ARTN 2005.0008 10.1038/msb4100012 (2005). 73 Diaz-Montero, C. M. et al. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer 115, 920-928, doi:10.1038/bjc.2016.263 (2016). 74 Welti, J. C. et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30, 1183-1193, doi:10.1038/onc.2010.503 (2011). 75 Gao, N. et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J Biol Chem 277, 31963-31971, doi:10.1074/jbc.M200082200 (2002). 76 Buffart, T. E. et al. Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients. Clin Proteom 18, doi:ARTN 8 10.1186/s12014-020-09306-6 (2021).
RkJQdWJsaXNoZXIy MTk4NDMw